In this new episode of the Independent Rx Forum podcast, NCPA’s Ronna Hauser, senior vice president of policy and pharmacy affairs, speaks with Antonio Ciaccia, president of 3 Axis Advisors, about his firm’s new research outlining the lost revenue, cash flow disruptions, and below-cost reimbursements that will hammer small and independent pharmacies should the Medicare Drug Price Negotiation Program go into effect Jan. 1, 2026, without significant modifications to the program. Listen here or wherever you get your podcasts.
NCPA
